Building upon the division’s strong legacy in the field of Inflammatory Bowel Disease (IBD), Dr. Longman will oversee and expand clinical, research and educational activities at the JRC.
The innate immune system is the body’s first line of defense against invading pathogens, but there has been a lack of information on what a “healthy” innate immune system looks like.
Pembrolizumab was administered to patients who had already undergone extensive chemotherapy for advanced esophageal cancer and who, subsequently, had not responded to any other treatment.
The newsletter’s feature was in recognition of Dr. Lee’s pivotal abstract that presented an evaluation of the gut microbiota in 169 kidney transplant recipients.
This therapy is primarily being studied for resistant prostate cancer that has spread and/or has not responded to hormonal therapy.
Dr. Faltas's study, entitled “APOBEC mutagenesis in bladder cancer: mechanisms and therapeutic opportunities,” will receive $840,000 over two years.
His lecture was entitled, “Advances in the Laboratory Diagnosis of Invasive Candidiasis & Their Therapeutic Implications.”
The event served to foster and expand research activities and collaborations at Weill Cornell Medicine between established and emerging leaders in their respective fields.
Drs. Douglas Nixon and Brad Jones will be expanding the division’s already strong standing of more than 30 years in pioneering cutting-edge clinical trials for HIV/AIDS.
This conference was designed to highlight research programs within the department, expand scientific collaborations, and promote the exchange of knowledge between trainees and senior investigators.
